Cor pondering its dosage dilemma

Cor Therapeutics Inc. discussed in more detail data from its Phase III trial of Integrelin in all comers in coronary angioplasty. The additional information last week served to reinforce the preliminary conclusion that the trial failed to meet its primary end point - a composite of death, myocardial infarction and the